These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86. The investigation of a cholesterol esterase in rat liver. SCHOTZ MC; RICE LI; ALFIN-SLATER RB J Biol Chem; 1954 Apr; 207(2):665-70. PubMed ID: 13163051 [No Abstract] [Full Text] [Related]
87. [Research on the cholesterol esterase system of rat liver]. METZGER EF; FAVARGER P Helv Physiol Pharmacol Acta; 1948; 6(3):C59. PubMed ID: 18893123 [No Abstract] [Full Text] [Related]
88. Lysosomal Acid Lipase Activity: A Tool for the Detection and Management of Fatty Liver Disease? Ramirez CM; Lopez AM; Turley SD EBioMedicine; 2015 Jul; 2(7):638-9. PubMed ID: 26286464 [No Abstract] [Full Text] [Related]
89. Cholesterol esterases. V. A cholesterol esterase of rat liver. BYRON JE; WOOD WA; TREADWELL CR J Biol Chem; 1953 Nov; 205(1):483-92. PubMed ID: 13117925 [No Abstract] [Full Text] [Related]
90. A mechanochemical approach to deracemization. Wiggins KM; Bielawski CW Angew Chem Int Ed Engl; 2012 Feb; 51(7):1640-3. PubMed ID: 22311813 [No Abstract] [Full Text] [Related]
92. The crucial role of ATGL for energy supply of muscles. Olivecrona G J Lipid Res; 2010 Mar; 51(3):449-50. PubMed ID: 20007838 [No Abstract] [Full Text] [Related]
93. The pharmacokinetic disposition of delta-9-tetrahydrocannabinol and its metabolite in elderly patients with dementia--role of differential presystemic conversion? Srinivas NR Psychopharmacology (Berl); 2016 Jan; 233(1):157-8. PubMed ID: 26537908 [No Abstract] [Full Text] [Related]
94. Correction to: Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging. Gilman JM; Schmitt WA; Potter K; Kendzior B; Pachas GN; Hickey S; Makary M; Huestis MA; Evins AE Neuropsychopharmacology; 2022 May; 47(6):1282. PubMed ID: 35228659 [No Abstract] [Full Text] [Related]
95. Expression of Concern: Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ Br J Pharmacol; 2023 Aug; 180(15):2035. PubMed ID: 37271499 [No Abstract] [Full Text] [Related]
96. Correction to: Effect of Lipid Vehicles on Solubility, Stability, and Topical Permeation of Delta-9-Tetrahydrocannabinol. Shankar VK; Shettar A; Rangappa S; Ellis I; Dave M; Murthy R; Murthy SN AAPS PharmSciTech; 2022 Aug; 23(7):240. PubMed ID: 36002709 [No Abstract] [Full Text] [Related]
97. Delta-8-tetrahydrocannabinol Associated Manic Switch: A Case Report. Raghunathan S; Purohith AN; Sharma PSVN Indian J Psychol Med; 2024 May; 46(3):280-281. PubMed ID: 38699772 [No Abstract] [Full Text] [Related]
98. Public health considerations about tetrahydrocannabinol-infused beverages. LoParco CR; Tillett KK; Chen-Sankey J; Berg CJ; Rossheim ME Addiction; 2024 Sep; ():. PubMed ID: 39327681 [No Abstract] [Full Text] [Related]
99. Hydrolysis of 11-palmitoyloxy-delta 9-tetrahydrocannabinol to 11-hydroxy-delta 9-tetrahydrocannabinol by cholesterol esterase and a lipase. Leighty EG Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):393-6. PubMed ID: 461993 [TBL] [Abstract][Full Text] [Related]
100. Comparison of the effects of 11-palmitoyloxy-delta 9-tetrahydrocannabinol with delta 9-tetrahydrocannabinol and 11-hydroxy-delta 9-tetrahydrocannabinol on the hepatic microsomal drug-metabolizing enzyme system. Leighty EG Res Commun Chem Pathol Pharmacol; 1979 Sep; 25(3):525-35. PubMed ID: 116333 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]